Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Philadelphia-based Blues affiliate Independence Blue Cross on Jan. 26 said it will launch an Advanced Network for Gene-Based Therapeutics in March of this year. The insurer is partnering with Penn Medicine and Children’s Hospital of Philadelphia in the creation of the new network, noting both providers “have played pivotal roles in the development and clinical trials of first-in-the-nation gene-based therapies.” While the network is intended to help Independence members access gene therapies, the press release noted that Luxturna and Zynteglo, both covered under Independence’s medical benefit, will “continue to require precertification.” Independence is currently the second-largest insurer in Pennsylvania, with 1,993,695 members.

Source: AIS’s Directory of Health Plans

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: CMS Reinstates Medicaid Coverage for 500,000 People

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 25

Datapoint: N.C. Blues Says Specialty Pharmacy Management Reduced Premiums

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Idaho Completes Medicaid Redeterminations

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today